Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

Interim results for 6 months end 31 December 2014
RNS
RNS Number : 3140G
Clinigen Group plc
03 March 2015



Clinigen Group plc

Half year revenues up 17% to £72.6m, underlying EBITDA up 8% to £13.5m

Burton-on-Trent, UK - 3 March 2015 - Clinigen Group plc (AIM: CLIN, Clinigen or the Group), the global specialty pharmaceuticals and pharmaceutical services business, has today published its half year results for the six months ended 31 December 2014.

Financial highlights

- Group revenue up 17% to £72.6m (H1FY14: £61.8m); on a constant exchange rate basis up 21%

- Gross profit up 11% to £22.0m (H1FY14: £19.9m)

- Underlying EBITDA* up 8% to £13.5m (H1FY14: £12.5m), despite significant additional new product integration investment

- Adjusted underlying earnings per share** up 12.6% to 12.5p (H1FY14: 11.1p). Reported earnings per share up 5.7% to 9.2p (H1FY14: 8.7p)

- Interim dividend up 10% to 1.1p per share (H1FY14: 1.0p per share)

- Net cash of £12.9m at 31 December 2014 (30 June 2014: £5.3m)

Business highlights

- CTS: 28% revenue growth, 14 new customers, underlying activity up (requests up 11%, medicines supplied up 13%)

- GAP: 51% increase in units shipped, seven new programs to start in CY15 including first program for AstraZeneca for their product CAZ-AVI. Fycompa program extended for a further 18 months

- SP: SP sales and gross profit up 21% driven by new products and underlying volume growth in Foscavir. Ethyol acquisition (August 2014) already contributing to revenues. Revitalisation plans for dexrazoxane portfolio of products, Cardioxane and Savene on track. Final Marketing Authorisations for Cardioxane transferred from Novartis, in February 2015.

* Underlying EBITDA is defined as earnings before interest, tax, depreciation and amortisation excluding share based payments and associated Employer's National Insurance

** Underlying earnings exclude share based payments, associated Employer's National Insurance costs, amortization and are adjusted for associated tax

Peter George, Chief Executive Officer, said:

"After another strong first half, with all three divisions making good profit contributions, we are in a great position to continue our ambitious pursuit to become the world leaders in Clinical Trial Services, Global Access Programs and have a Specialty Pharmaceutical portfolio with 10 revitalized products.

"For the second half of the year gaining regulatory clearance for our dexrazoxane portfolio of drugs is a priority, along with the constant drive to convert the pipeline of new business and extend current customer relationships within CTS and GAP. In addition, we continue to explore opportunities to extend our global footprint and unlicensed supply market position.

"We anticipate another busy six months ahead."

-Ends-

An analyst briefing will be held at 9:30am today at the offices

3 Mar Investec N/A Hold
3 Mar Numis 770.00 Buy

Clinigen Extends Foscavir US Distribution Contract
RNS
RNS Number : 0764H
Clinigen Group plc
11 March 2015



Clinigen Group Extends Exclusive Foscavir® US Distribution Agreement
with Hospira to 2019

Burton on Trent, UK - 11 March 2015 - Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN) today announces the extension and renegotiation of the exclusive license and distribution agreement with Hospira, Inc ('Hospira') for its anti-viral product Foscavir® (foscarnet sodium) in the US. This is expected to be beneficial to both parties.

The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.

Foscavir® is Clinigen's lead product. Foscavir® received FDA approval in May 2012 for the treatment of HIV/AIDS-related cytomegalovirus infections and herpes. In September 2014, the FDA recognized the determined efforts made by Clinigen in providing Foscavir® to patients in the US by awarding Clinigen the first Drug Shortage Assistance Award.

Peter George, Chief Executive Officer, Clinigen Group said: "Hospira has been an excellent partner in the US, working closely with Clinigen since we acquired Foscavir®. The new five year agreement recognizes the strength of this partnership and shows the commitment of both Hospira and Clinigen to the continued supply of Foscavir® to US patients."

- Ends

UPDATE - Clinigen extends US distribution agreement for lead product

By John Harrington

March 11 2015, 4:39pm
The original distribution agreement with Hospira expired in May 2017, but this has now been extended until the end of 2019.



---ADDS BROKER COMMENT---

Clinigen (LON:CLIN) has renegotiated and extended its exclusive licence and distribution agreement with Hospira for its Foscavir treatment for HIV.

The agreement was due to expire in May December but not runs to the end of 2019 in a move that Clinigen said is expected to be beneficial to both parties.

Peter George, Clinigen’s chief executive, said: "Hospira has been an excellent partner in the US, working closely with Clinigen since we acquired Foscavir. The new five year agreement recognizes the strength of this partnership and shows the commitment of both Hospira and Clinigen to the continued supply of Foscavir to US patients."

Broker N+1 Singer reiterated its ‘buy’ recommendation and said: “Last week, in our sector piece, we upgraded our target price on Clinigen to 590p. At the time, we highlighted that we expected its portfolio of Specialty Pharma therapies to see good ongoing growth. Today’s announcement supports this.”

11 Mar N+1 Singer 590.00 Buy

Finally some appeal returning here. A new 52 week high today and more importantly we've broken the Nov14 high. Next stop 650P? - and perhaps quite rapidly after not having done much since the autumn.

Peel Hunt - buy - 717p
Investec - hold - 546p
N+1 Singer - buy - 590
Numis - buy - 770p

17 Apr Investec 550.00 Hold

Broker spotlight - Investec has put a hold rating on drugs distributor Clinigen (LON:CLIN).

A review of its competitive situation and key products suggests it can continue to grow its portfolio, but services is not growing as fast as expected so the broker downgrading earnings estimates down the road. Target price is 550p. Hold is the view.

Acquisition

£225 million Acquisition of Idis and £135 million Vendor Placing

It had to come soon, next shift upwards. Great news - haven't digested it all yet.

Blue sky coming...

Numis target price 860p

ROUNDUP – Clinigen shares jump as investors give £225mln acquisition the thumbs-up

By Ian Lyall

April 24 2015, 2:51pm
Some £2.5mln of revenue and cost synergies have been identified


---ADDS BROKER COMMENT---

Shares in the speciality pharma group Clinigen (LON:CLIN) jumped over 7% after it unveiled the £225mln acquisition of Idis Group - a deal that will create a market leader in the ethical unlicensed supply of medicines.

The purchase will be funded from Clinigen’s new debt facility and a £135mln vendor placing and is expected to be ‘significantly’ earnings enhancing in the first full year after the transaction.

Some £2.5mln of revenue and cost synergies have been identified.

But chief executive Peter George told Proactive Investors: “The real savings in this business are about driving growth through the business and changing some of the commercial terms in our business.

“So I think we will drive profit through the gross profit line much faster than we would through synergy savings because this is about a growth plan, not a cost saving plan.

“We want to hit the ground running and take the market by storm. This isn’t going to be done by making cuts in the business. That’s not what this is about.”

The companies will be filling a gap in the market by bringing potentially life-saving medicines to countries where they are not currently licensed.

A quirk of the current system is that many drugs and treatments that might have regulatory and safety clearance in the major developed or developing countries, remain unsanctioned in other territories.

“We want to become the healthcare professional solution for hospital pharmacies and clinicians to access unlicensed medicines in an ethical and completely controlled way,” George said.

Clinigen believes there is a major growth opportunity in combining the two businesses to create the biggest player in the ethical unlicensed supply market, which is estimated to be worth in excess of US$5bn a year.

“On completion, Clinigen, as the market leader, will be well placed to shape and define this fast growing and critically important market,” the company told investors.

Following the news, broker Numis repeated a 'buy' rating and upgraded its price target by 12% to 860p.

Meanwhile, broker Stifel said the acqusition would diversify Clinigen's business away from its over dependence on the antiviral drug Foscavir.

"However, Clinigen has retained the flexibility to make further bolt-on acquisitions of specialty pharma products. The deal clearly makes financial sense since it is earnings enhancing from the start as well as making Clinigen by far the largest player in the supply of unlicensed medicines."

Headquartered in Weybridge, in Surrey, Idis has established a significant business over the past 25 years supplying drugs predominantly on an exclusive basis through managed access programmes and on-demand through its general access division.

In the year ended February its revenues were just under £197mln, while earnings before interest, tax, depreciation and amortisation were £15.6mln.

“This acquisition satisfies a number of our key strategic goals - achieving the market leader position in the $5bn-plus unlicensed medicine supply sector and strengthening our leading position in the $2bn clinical trial supply market,” George said.

"The acquisition will also accelerate our growth and gives us a much better balanced portfolio of businesses, whilst extending our unique business model.

"The enlarged entity creates an incredibly exciting business with tremendous opportunities for growth.

“I am confident that, together with Idis, we have the right people to define and shape the unlicensed medicine supply market - an increasingly important health care sector for patients with unmet needs."

The deal is a particularly good one for CBPE, the private equity owner of Idis, which invested £9.4mln buying the business in 2005.

Idis managing director Tony Dutta said: “IDIS is now the clear market leader in a market with highly attractive long term growth fundamentals.

“CBPE have been an outstanding, partner, fully supporting us as we have grown the business over the long term.

“The acquisition by Clinigen marks the beginning of a new and exciting chapter in the continued development of the business.”

Clinigen’s investors reacted positively to the acquisition, helping push the stock up 47p to 572.5p, valuing the business at £466mln.

We've not seen the 6 big figure for some time. Rapidly up to life highs now?

Stifel new buy today, tp 650p

Yehaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

Nice write-up in this week's IC before Idis acquisition.

easily missed this one :-(
congrats to all those who did not

cynic, notwithstanding the current spike, the latest acquisition could be a game changer, so you may not have missed it on a correction. And then how long before big pharma sniff around...

thanks you old dog .... i'll keep a weather eye open